AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims
Executive Summary
'Amgen is speaking out of both sides of its mouth', AbbVie contends, promising suit on dozens more patents.
You may also be interested in...
Humira's 'Unique' Number Of Patents Makes Biosimilar Entry Risky, Pfizer Says
Pfizer wants to get its adalimumab biosimilar to market as soon as possible, but won’t say whether that’s before AbbVie's patents run out in 2023.
Humira's 'Unique' Number Of Patents Makes Biosimilar Entry Risky, Pfizer Says
Pfizer wants to get its adalimumab biosimilar to market as soon as possible, but won’t say whether that’s before AbbVie's patents run out in 2023.
Humira Biosimilar Settlement Could Be Model For Other Disputes
Agreement with AbbVie allows Amgen to launch its Humira biosimilar in Europe in 2018 and in the US in 2023; it may be akin to generic settlements but it is uncertain if other sponsors will get similar deals.